Nuclera

Nuclera Awarded £1.14m Innovate UK Funding for Development of eProtein Discovery

£790,000 FASST grant, in collaboration with DeepMirror, and £350,000 Engineering Biology grant awarded for platform development 6 June 2024 -- Cambridge, UK -- Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop eProtein Discovery system, today announced it has been awarded two highly competitive Innovate UK grants totalling £1.14m. The funding,...

Nuclera eProtein Discovery system installed at leading academic institutes

11 installs successfully completed Novel platform automates and accelerates protein production, enabling scale-up to mg amount in less than 48 hours List of institutes includes, University College London, University of Cambridge, University of Southampton, University of Manchester, and the CRUK Cambridge Institute, all UK, and The Flanders Institute for Biotechnology (VIB) in Belgium. 2 May...

Nuclera joins Tech Nation’s Future Fifty Programme

Nuclera recognised as one of UK’s most exciting growth stage companies Official launch of 2024 cohort taken place at 10 Downing Street 19 March 2024 – Cambridge, UK – Nuclera, the biotechnology company enabling rapid protein expression and purification screening through its eProtein Discovery benchtop protein platform, today announced it has been selected to join...

Nuclera appoints Joseph Bertelsen as Chief Commercial Officer

Key appointment to lead global commercial launch of eProtein Discovery platform 14 March 2024 – Cambridge, UK – Nuclera, the biotechnology company enabling rapid protein expression and purification screening through its benchtop protein platform, today announced the appointment of Joseph Bertelsen as chief commercial officer (CCO). With over 20 years’ commercial leadership experience in the...
One Vision Park, Station Road, Impington, Cambridge, CB24 9NP

+44 1223 625095